Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

By Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, N. Minato. Proceedings of the National Academy of Sciences of the United States of America, 2002

3,014 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/7baa256510293652d96992a827f1b6061fda57ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. D. Pardoll
3. G. Freeman
4. W. Zou
5. Arlene H. Sharpe
6. E. Wherry
7. James P. Allison
8. Antoni Ribas

In Oncology

1. Lieping Chen
2. D. Pardoll
3. G. Freeman
4. W. Zou
5. Arlene H. Sharpe
6. E. Wherry
7. James P. Allison
8. Antoni Ribas

Citations in the corpus

• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005, background): “Blockade of B7-H1 by 10B5 mAb inhibited apoptosis of activated alloreactive 2C T cells, suppressed growth of P815 cells in vivo (12), and blocked B7-H1-mediated promotion of P815 tumor growth (29).”
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (2010, background): “It is unlikely that this represents a direct antitumor effect, because B16 melanoma expresses little to no PD-L1 in vivo (22).”
• Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress (2018, background): “Further relevance for such a dual-targeting approach comes from the observation that melanoma cells can upregulate surface expression of the PD-L1 ligand in response to IFNg to suppress T cell function through activation of inhibitory PD1 receptor signaling (Iwai et al., 2002; Taube et al., 2012).”
• PD-1 and its ligands in tolerance and immunity. (2008, background): “Treatment with anti-PD-L1 in vivo delays, but does not halt, tumorigenesis of PDL1-expressing mouse myeloma cell lines (137) PD-L1 blockade can improve the outcome of immunotherapy.”
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003, background): “(26), in a tumor immunity model, recently demonstrated that transgenic expression of PD-L1 in tumor cells rendered them less susceptible to the specific T cell antigen receptor–mediated lysis by cytotoxic T cells.”
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 (2003, background): “(41) have shown that PD-L1 inhibits CD8 T cell-mediated cytolysis.”
• Overcoming T cell exhaustion in infection and cancer (2015, background): “In many mouse tumor systems, PD-1 pathway blockade is often administered early at time points when full exhaustion may not yet have developed [12, 13, 36, 117, 120].”
• CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “In contrast, in chronic infections and cancer PD-1 expression is maintained at high levels on Tex cells (15, 45, 69, 95, 134, 215).”